Several times in 2018, an Epi-Pen shortage has been advised. The one manufacturer in Canada, Pfizer, has cited manufacturing issues as the reason. This all too common shortage is hard to understand, given the steadily increasing need for this essential antidote for serious allergic reaction.

What can be done to ensure that an essential EpiPen supply is guaranteed? The solution is clear: The need to have several streams of distribution through more than one company will provide options for choice and availability. If necessary, this supply can made available to Pfizer, to ensure that there is no shortage.

If several companies at present in Canada do have the capacity to provide safe and effective EpiPens, that path should be cleared for approval. Health Canada and advocacy groups can play a pivotal role. Ensuring EpiPen availability is essential ASAP.